#United States #New York #Class Action #Rocket Pharmaceuticals #RCKT

Alert for Rocket Pharmaceuticals Investors

Levi & Korsinsky, LLP has issued a notification to investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) regarding an active class action lawsuit. The firm aims to recover losses experienced by shareholders following allegations surrounding the company’s financial disclosures and conduct. Those affected are encouraged to take action before the approaching deadline.

Class Action Lawsuit Overview

This class action lawsuit targets Rocket Pharmaceuticals, particularly concerned with potential securities fraud that occurred between February 27, 2025, and May 26, 2025. The lawsuit aims to represent investors adversely impacted during this period due to misleading statements and omissions by the company.

As the details emerge, the complaint outlines that Rocket Pharmaceuticals allegedly promoted a notably positive image concerning the safety and efficacy of its treatment, RP-A501. However, they simultaneously failed to disclose critical adverse events experienced by trial participants, which included serious health risks and, tragically, participant deaths.

Background of Allegations

The allegations specify that Rocket Pharmaceuticals made multiple positive assertions to investors while hiding crucial realities about the clinical trial protocols for RP-A501. Notably, it is stated that substantial protocol changes were made without informing shareholders, which concealed the associated risks of serious adverse events (SAEs).

On May 27, 2025, the company revealed that the FDA imposed a clinical hold on the RP-A501 Phase 2 pivotal study following the death of one participant, who had been enrolled in the trial under the amended protocol that had not been disclosed at the time. This lack of transparency led to a drastic decline in the stock price, dropping nearly 37% the day news broke about the clinical hold.

The Road Ahead: Lead Plaintiff Step

For those investors who suffered losses during this period, the deadline to apply for lead plaintiff status in the class action lawsuit is August 11, 2025. It's important to note that participation in any potential recovery from this lawsuit does not require being appointed as a lead plaintiff; affected investors can still claim compensation without that designation.

If you are an investor who has been impacted, you should reach out to Levi & Korsinsky, either through direct contact with Joseph E. Levi, Esq. or by visiting their website for additional information. Investors can reach out via email at [email protected] or call at (212) 363-7500 to discuss their claims and options.

No Costs Involved

One of the significant factors in this notification is the assurance that there are no costs to class members to participate in the lawsuit. Class members are entitled to potential compensation without any associated out-of-pocket expenses, making it accessible for all affected investors to engage.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has built a reputable brand over the last two decades, securing hundreds of millions for aggrieved shareholders. Their success in managing complex securities litigation cases is backed by a dedicated team of over 70 professionals committed to delivering results for their clients. Their acknowledged accomplishments, including ranking as one of the top firms in ISS Securities Class Action Services' Top 50 Report, provide further assurance to prospective class members of their trustworthiness and expertise.

Conclusion

This class action lawsuit brings to the forefront critical concerns regarding shareholder trust and corporate accountability. As the deadline for lead plaintiff applications approaches, affected investors need to remain proactive in seeking legal counsel and securing their rights. Levi & Korsinsky remains a pivotal player in representing those impacted and stands ready to assist investors in navigating this essential process.